Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension-Reference-Cited by-全球学者库

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension

Published:2021-05 Issue: Volume:50 Page:102849
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Kim Ho Jin^ORCID,Nakashima Ichiro,Viswanathan Shanthi,Wang Kai-Chen,Shang Shulian,Miller Larisa,Yountz Marcus,Wingerchuk Dean M.^ORCID,Pittock Sean J.,Levy Michael,Berthele Achim^ORCID,Totolyan Natalia,Palace Jacqueline,Barnett Michael H.,Fujihara Kazuo

Funder

Alexion Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference41 articles.

1. Pharmacokinetic/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the phase 3 PREVENT study;Berthele;Eur. J. Neurol.,2020

2. Meningococcal disease in the Asia-Pacific region: findings and recommendations from the Global Meningococcal Initiative;Borrow;Vaccine,2016

3. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria;Brodsky;Blood,2008

4. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial;Cree;Lancet,2019

5. EuroQol Research Foundation, 2018. EQ-5D-3L user guides. 2018. https://euroqol.org/publications/user-guides. Accessed December 7, 2020.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study;Multiple Sclerosis and Related Disorders;2023-11

2. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment;Multiple Sclerosis and Related Disorders;2023-11

3. A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder;Current Neurology and Neuroscience Reports;2023-08-04

4. New advancements in the management of Neuromyelitis Optica spectrum disease: literature review;Frontiers in Ophthalmology;2023-05-16

5. Systematic Review of Treatment Options and Therapeutic Responses for Lesions of the Sella and Orbit: Evidence-Based Recommendations;World Neurosurgery;2023-05